A patient-derived tumoroid platform for NF1 low-grade glioma shows myeloid evolution and shifting metabolic dependencies during in vitro culturing
About 10–15% of individuals with Neurofibromatosis Type 1 develop a low-grade glioma (LGG) within the optic pathway, and an additional 3–5% of individuals develop LGG outside of the optic pathway. In recent years molecular analysis has greatly enhanced our understanding of what drives these NF1 LGG; however, to date...